Self-Reported Walking Pace and Risk of Cardiovascular Diseases: A Two-Sample Mendelian Randomization Study

Lu Chen†, Xingang Sun†, Yuxian He and Liangrong Zheng*

Department of Cardiology and Atrial Fibrillation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Background: In observational studies, the self-reported walking pace has been associated with the risk of cardiovascular diseases (CVD). However, whether those associations indicate causal links remains unclear. We performed two-sample Mendelian randomization (MR) analyses to evaluate the causal effect of walking pace on several CVD outcomes, including atrial fibrillation (AF), heart failure (HF), any stroke, ischemic stroke (IS), and IS subtypes.

Methods: Genetic variants associated with self-reported walking pace were selected as instrumental variables (IVs) from the latest genome-wide association studies (GWAS). Summary-level data for outcomes were obtained from the corresponding GWAS and the FinnGen consortium. The random-effects inverse variance weighted (IVW) method was used as the main MR analysis, supplemented by replication analyses using data from the FinnGen. To explore the effect of pleiotropy due to adiposity-related traits, we further conducted MR analyses by excluding the adiposity-related IVs and regression-based multivariable MR adjusting for body mass index (BMI).

Results: The MR results indicated significant inverse associations of self-reported walking pace with risks of AF [odds ratio (OR), 0.577; 95% confidence interval (CI), 0.442, 0.755; \( p = 5.87 \times 10^{-5} \)], HF (OR, 0.307; 95% CI, 0.229, 0.413; \( p = 5.31 \times 10^{-15} \)), any stroke (OR, 0.540; 95% CI, 0.388, 0.752; \( p = 2.63 \times 10^{-4} \)) and IS (OR, 0.604; 95% CI, 0.427, 0.853; \( p = 0.004 \)) and suggestive inverse association of self-reported walking pace with cardioembolic stroke (CES) (OR, 0.492; 95% CI, 0.259, 0.934; \( p = 0.030 \)). Similar results were replicated in the FinnGen consortium and persisted in the meta-analysis. However, there was no causality between walking pace and large artery stroke (OR, 0.676; 95% CI, 0.319, 1.434; \( p = 0.308 \)) or small vessel stroke (OR, 0.603; 95% CI, 0.270, 1.349; \( p = 0.218 \)). When excluding adiposity-related IVs and adjusting for BMI, the associations for HF and any stroke did not change substantially, whereas the associations for AF, IS, and CES were weakened.

Conclusion: Our findings suggested that genetically predicted increasing walking pace exerted beneficial effects on AF, HF, any stroke, IS, and CES. Adiposity might partially mediate the effect of walking pace on AF, IS, and CES.

Keywords: self-reported walking pace, atrial fibrillation, heart failure, stroke, Mendelian randomization, causal association

†These authors have contributed equally to this work and share first authorship.
INTRODUCTION

Walking is an acceptable, simple, safe, and cheap kind of physical activity for the population, and it is widely promoted with its physical, mental, and social health benefits (Murtagh et al., 2015; Stamatakis et al., 2019). However, the primary focus is to increase the walking time and the number of walking steps, with the role of walking pace poorly explored (Celis-Morales et al., 2019).

As an easy and reliable measure of functional capacity, walking pace has been identified as a strong predictor of mortality and risk of cardiovascular diseases (CVD). Previous studies consistently suggested that objectively assessed walking pace was inversely associated with all-cause mortality and CVD risk (Dumurgier et al., 2009; Liu et al., 2016; Celis-Morales et al., 2019; Stamatakis et al., 2019). Recently, Timmins et al. conducted a genome-wide association study (GWAS) of self-reported walking pace and clarified the genetic associations of walking pace with a range of health outcomes (Timmins et al., 2020). They indicated that genetically predicted self-reported walking pace was associated with a lower risk of coronary artery disease (CAD) [odds ratio (OR) = 0.34, p = 3.1 × 10^{-8}] (Timmins et al., 2020). However, whether such causal association extends to other CVD outcomes remains unknown. Notably, several observational studies showed that walking pace was significantly associated with the risk of atrial fibrillation (AF) (Mozaffarian et al., 2008; Koca et al., 2020) and heart failure (HF) (Saevereid et al., 2014) as well as stroke (Quan et al., 2020).

Mendelian randomization (MR) is a credible and powerful approach to study the causal associations between exposures and outcomes. This approach uses genetic variants which have a specific effect on a trait (exposure) as instrumental variables (IVs). Considering that genetic variants are randomly allocated at conception and thus uncorrelated with any self-adopted or environmental factors, the MR approach can minimize residual confounding (Emdin et al., 2017). Furthermore, since genetic instruments are nonmodifiable, the MR approach estimates the effect of lifelong exposure and avoids reverse causation (Sekula et al., 2016). Therefore, we conducted a two-sample MR study to investigate the causal relationships between self-reported walking pace and several CVD outcomes, including AF, HF, any stroke, ischemic stroke (IS), and IS subtypes. We also replicated the MR association of self-reported walking pace with rheumatoid arthritis (RA), which was previously reported as null-association (Timmins et al., 2020), to further test the validity of our results.

MATERIALS AND METHODS

Study Design

This study applied a two-sample MR design to estimate the causal inference between self-reported walking pace and CVD risks. The MR study was built upon three assumptions. First, the IVs were significantly associated with exposure (self-reported walking pace). Second, the IVs should be independent of any confounders. Third, the IVs directly affected the outcome (CVD) only through exposure rather than other pathways.

Data Sources and IV Selection

We conducted this two-sample MR study using summary-level data from previously published large-scale GWAS. The detailed descriptions of data sources are presented in Supplementary Table S1. According to the first key assumption of MR, we utilized 75 lead uncorrelated single nucleotide polymorphisms (SNPs) (linkage disequilibrium threshold of $r^2 < 0.1$) as the genetic instruments for self-reported walking pace, which were reported at genome-wide significance ($p < 5 \times 10^{-8}$) in the GWAS utilizing the United Kingdom Biobank data (Timmins et al., 2020). This study included 450,967 participants (average age 58 and 45.7% of them were male) who reported the walking pace as a category phenotype: “slow,” “steady/average,” or “brisk,” and this phenotype was coded 0, 1, and 2, respectively, to further use a linear mixed model with covariates for age, sex, genotyping array, and 20 principal components of ancestry implemented (Timmins et al., 2020). F-statistic for each IV was calculated to evaluate the strength of the relationship between IV and self-reported walking pace (Supplementary Table S1). SNP with F-statistic $>10$ was generally recommended as an indication of strong IV (Burgess and Thompson, 2011). CVD outcomes included AF, HF, any stroke, IS, and IS subtypes in this study. The summary-level data for these outcomes were obtained from GWAS meta-analysis (Nielsen et al., 2018), the HERMES consortium (Shah et al., 2020), the MEGASTROKE consortium (Malik et al., 2018), and the FinnGen consortium (FinnGen Consortium, 2021). If IVs were not available in the outcome database, proxy SNPs would be searched online (http://snipa.helmholtz-muenchen.de/snipa3/) to replace them, and the proxy searching results are presented in Supplementary Table S2. Moreover, for each CVD outcome, IVs directly associated ($p < 5 \times 10^{-8}$) with each CVD outcome were excluded from our analyses. After extracting the summary-level data, we further harmonized the exposure and outcome data to ensure the effect of an SNP on the exposure and the effect of that SNP on the outcome each corresponding to the same allele.

Statistical Analysis

The multiplicative random-effects inverse variance weighted (IVW) method was used as the main MR method to assess the causal inferences between self-reported walking pace and CVD outcomes. The replication analyses were also performed to validate the reliability of the results using summary-level data from the FinnGen consortium (Table 1). Then, the fixed-effects meta-analysis method was used to combine the MR estimates from different data sources. Several complementary MR analyses were used to provide credible estimates and detect pleiotropy, including the weighted median (Bowden et al., 2016), MR-robust-adjusted profile score (MR-RAPS) (Zhao et al., 2018), MR-Egger (Bowden et al., 2015), and the MR-pleiotropy residual sum and outlier (MR-PRESSO) (Verbanck et al., 2018) methods. The weighted median method assumed that the weights were equal and this assignment was done using the logit scores derived from the individual GWAS. The MR-RAPS corrected for horizontal pleiotropy in the IVW analysis (Zhao et al., 2018). The MR-Egger generated MR estimates after correction for pleiotropy (Bowden et al., 2015). Moreover, the MR-PRESSO provided robust MR estimates by excluding the identified outliers (Verbanck et al., 2018). Besides, we chose RA
First, we calculated the I² index and displayed the scatter plots and funnel plot to identify the possible heterogeneity among IVs. An I² index >25% was deemed as the marker of heterogeneity (low: 25% < I² < 50%; moderate: 50% < I² < 75%; high: I² > 75%). Second, the intercept test from the MR-Egger regression-based multivariable MR (MVMR) was conducted to measure pleiotropy (Bowden et al., 2015). Third, we performed the leave-one-out analysis to evaluate the consistency of causal associations and whether any individual SNP affected the results.

Since the selected IVs should be independent of any confounders and exert an effect on the outcome only through the exposure, we further conducted analyses to explore the effect of pleiotropy due to adiposity-related traits, as several of the selected IVs are associated with the body mass index (BMI) and weight according to the PhenoScanner (http://www.phenoscanner.medschl.cam.ac.uk) and Open Target Genetics platform (https://genetics.opentargets.org) (Supplementary Tables S3, S4). First, MR analyses were re-conducted after excluding these SNPs which were previously associated with BMI or weight. Second, we additionally implemented the regression-based multivariable MR (MVMMR) according to Yavorska and Burgess (2017) to obtain the direct MR

### TABLE 1 | Characteristics of the data sources.

| Trait                          | Data source                      | Sample size (case/control) | Ancestry | Use                        | Phenotype/case definition                                                                 | Covariates adjusted in GWAS                                                                 |
|-------------------------------|----------------------------------|-----------------------------|----------|----------------------------|--------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| Self-reported walking pace    | Timmins et al. (2020)            | 450,967                     | European | Exposure                   | Category phenotype: “slow,” “steady/average,” or “brisk”                                    | Age, sex, genotyping array, and the first 20 principal components of ancestry, birth year, sex, genotype batch, and principal components 1–4 |
| Atrial fibrillation           | Nielsen et al. (2018)            | 60,620/970,216              | European | Outcome                    | ICD-10 code I48                                                                            | Sex, age, 10 principal components, and genotyping batch                                    |
| Atrial fibrillation           | FinnGen Consortium (2021)        | 22,068/116,926              | European | Outcome for replication analyses | ICD-10 code I48                                                                            | Sex, age, 10 principal components, and genotyping batch                                    |
| Heart failure                 | HERMES Shah et al. (2020)       | 47,309/900,014              | European | Outcome                    | Self-reported, physician diagnosis, or the ICD-9 or ICD-10 codes for discharge diagnosis   | Age, sex, and principal components in individual studies, where applicable                  |
| Heart failure                 | FinnGen Consortium (2021)        | 23,397/194,811              | European | Outcome for replication analyses | ICD-10 code I11.0, I13.0, I13.2, I50                                                       | Sex, age, 10 principal components, and genotyping batch                                    |
| Any stroke                    | MEGASTROKE Malik et al. (2018)  | 40,585/406,111              | European | Outcome                    | Rapidly developing signs of focal (or global) disturbance of cerebral function, lasting more than 24 h or leading to death with no apparent cause other than that of vascular origin | Age and sex                                                                                 |
| Any stroke                    | FinnGen Consortium (2021)        | 18,661/162,201              | European | Outcome for replication analyses | ICD-10 code I60, I61, I62, I63, I64, G45                                                   | Sex, age, 10 principal components, and genotyping batch                                    |
| Ischemic stroke               | MEGASTROKE Malik et al. (2018)  | 34,217/406,111              | European | Outcome                    | IS was defined based on clinical and imaging criteria                                       | Age and sex                                                                                 |
| Ischemic stroke               | FinnGen Consortium (2021)        | 10,551/202,223              | European | Outcome for replication analyses | ICD-10 code I63, I64                                                                      | Sex, age, 10 principal components, and genotyping batch                                    |
| Large artery stroke           | MEGASTROKE Malik et al. (2018)  | 4,373/146,392               | European | Outcome                    | Trial of Org 10172 in Acute Stroke (TOAST) criteria                                         | Age and sex                                                                                 |
| Small vessel stroke           | MEGASTROKE Malik et al. (2018)  | 5,386/192,668               | European | Outcome                    | Trial of Org 10172 in Acute Stroke (TOAST) criteria                                         | Age and sex                                                                                 |
| Cardioembolic stroke          | MEGASTROKE Malik et al. (2018)  | 7,193/204,570               | European | Outcome                    | Trial of Org 10172 in Acute Stroke (TOAST) criteria                                         | Age and sex                                                                                 |
| Rheumatoid arthritis          | Okada et al. (2014)              | 14,361/42,923               | European | Negative control outcome   | 1987 criteria of the American College of Rheumatology for RA diagnosis or were diagnosed as RA by a professional rheumatologist | Top 5 or 10 principal components                                                             |
| Body mass index               | Hoffmann et al. (2018)           | 334,487                     | Mixed (94.3% European) | Confounder for MVMMR analyses                                                                 | Weight (kg/height (m)²                                                                     | Age, sex, and ancestry                                                                     |

Abbreviations: GWAS, genome-wide association studies; ICD, International Classification of Diseases; ECG, electrocardiogram; MVMR, regression-based multivariable MR.
estimates independent of BMI. The summary statistic data for genetic associations of IVs with BMI were extracted from large meta-analysis of GWAS (Hoffmann et al., 2018).

We used a web-based application (https://cnsgenomics.com/shiny/mRnd/) to calculate the post hoc statistical power. Supplementary Table S5 shows the required minimum effect of self-reported walking pace on CVD outcomes to reach 80% statistical power based on the variance explained by the selected IVs (~0.92%) and sample sizes of outcomes.

The results were presented as ORs and corresponding 95% confidence intervals (CIs), which were scaled per category increase in the self-reported walking pace (slow, steady/average, and brisk). The Bonferroni method was used to account for multiple comparisons (eight outcomes). The associations with \( p \)-values < 0.006 (0.05/8) were regarded as statistically significant associations, and associations with \( p \)-values between 0.05 and 0.006 were considered as suggestive associations. The summary-level data used in this study were publicly available, and no ethics approval or informed consent was required. All analyses were conducted in R foundation (Version 4.0.2) by using package TwosampleMR (Hemani et al., 2018), MR-PRESSO (parameters: NbDistribution = 2,500, SignifThreshold = 0.05) (Verbanck et al., 2018), and Mendelian randomization (Yavorska and Burgess, 2017).

RESULTS

Our MR analyses found significant inverse associations of self-reported walking pace with risks of AF in the GWAS meta-analysis of Nielsen et al. (OR, 0.577; 95% CI, 0.442, 0.755; \( p = 5.87 \times 10^{-5} \)), HF in the HERMES (OR, 0.307; 95% CI, 0.229, 0.413; \( p = 5.31 \times 10^{-15} \)), any stroke (OR, 0.540; 95% CI, 0.388, 0.752; \( p = 2.63 \times 10^{-4} \)) and IS (OR, 0.604; 95% CI, 0.427, 0.853; \( p = 0.004 \)) and suggestive inverse association of self-reported walking pace with cardioembolic stroke (CES) (OR, 0.492; 95% CI, 0.259, 0.934; \( p = 0.030 \)) in the MEGASTROKE (Figure 1). There was no causal association between genetically predicted walking pace and large artery stroke (LAS) (OR, 0.676; 95% CI, 0.319, 1.434; \( p = 0.308 \)) or small vessel stroke (SVS) (OR, 0.603; 95% CI, 0.270, 1.349; \( p = 0.218 \)) (Figure 1). The significant associations for AF and HF were replicated in the FinnGen consortium and persisted in the meta-analysis (Figure 1). Although the association for any stroke was attenuated and the association for IS was not replicated in the FinnGen dataset, the meta-analysis supported the causal associations (Figure 1).

Sensitivity analyses showed that there was low heterogeneity for AF, HF, any stroke, and SVS indicated by the \( I^2 \) index, scatter plot, or funnel plot (\( I^2 = 42.3\% \) for AF, \( I^2 = 37.2\% \) for HF, \( I^2 = 37.2\% \) for any stroke, and \( I^2 = 37.2\% \) for SVS, respectively,

| Outcomes               | Data source | Case | SNPs | OR (95% CI)        | \( p \)-value |
|------------------------|-------------|------|------|--------------------|---------------|
| Atrial fibrillation    | Nielsen et al. | 60,620 | 72   | 0.577 (0.442, 0.755) | 5.87 \times 10^{-5} |
| Atrial fibrillation    | FinnGen     | 22,068 | 72   | 0.451 (0.265, 0.767) | 0.003         |
| Meta–analysis          |             |       |      | 0.549 (0.432, 0.698) | 9.07 \times 10^{-7} |
| Heart failure          | HERMES      | 47,309 | 73   | 0.307 (0.229, 0.413) | 5.31 \times 10^{-15} |
| Heart failure          | FinnGen     | 23,397 | 74   | 0.307 (0.209, 0.451) | 1.92 \times 10^{-6} |
| Meta–analysis          |             |       |      | 0.307 (0.243, 0.388) | 6.27 \times 10^{-23} |
| Any stroke             | MEGASTROKE  | 40,585 | 72   | 0.540 (0.388, 0.752) | 2.63 \times 10^{-4} |
| Any stroke             | FinnGen     | 18,661 | 74   | 0.597 (0.401, 0.887) | 0.011         |
| Meta–analysis          |             |       |      | 0.562 (0.436, 0.725) | 9.20 \times 10^{-6} |
| Ischemic stroke        | MEGASTROKE  | 34,217 | 72   | 0.604 (0.427, 0.853) | 0.004         |
| Ischemic stroke        | FinnGen     | 74    |      | 0.641 (0.392, 1.049) | 0.077         |
| Meta–analysis          |             |       |      | 0.616 (0.464, 0.817) | 7.90 \times 10^{-4} |
| Large artery stroke    | MEGASTROKE  | 4,373  | 72   | 0.676 (0.319, 1.434) | 0.308         |
| Small vessel stroke    | MEGASTROKE  | 5,386  | 72   | 0.603 (0.270, 1.349) | 0.218         |
| Cardioembolic stroke   | MEGASTROKE  | 7,193  | 72   | 0.492 (0.259, 0.934) | 0.030         |
| Rheumatoid arthritis   | Okada et al. | 14,361 | 71   | 0.771 (0.420, 1.417) | 0.402         |

FIGURE 1 | Associations of genetically predicted self-reported walking pace with risk of cardiovascular diseases. Abbreviations: SNPs, single nucleotide polymorphisms; OR, odds ratio; CI, confidence interval; HERMES, Heart Failure Molecular Epidemiology for Therapeutic Targets.
heterogeneity was observed for IS, LAS, or CES (I² = 24.8% for IS, I² = 2.8% for LAS, and I² = 19.4% for CES, respectively, Supplementary Table S6; Supplementary Figures S5–S7). The MR-Egger intercept test showed no evidence of horizontal pleiotropy in the analyses (Supplementary Table S6). Additionally, the leave-one-out analysis demonstrated that the overall causal effects for most CVD outcomes were not driven by any individual SNP (Supplementary Figures S1–S7), except that the potential causal relationship between walking pace and CES was modestly influenced by rs273512 (Supplementary Figures S7C).

We further conducted other MR methods to evaluate the robustness of our results. The MR estimates remained stable and robust in the weighted median and MR-RAPS methods. Nevertheless, the estimates deviated toward a null association in MR-Egger analyses except for any stroke (Table 2). Two SNPs (rs12127073 and rs9972653) for AF and two SNPs (rs7924036 and rs9972653) for HF were identified as outliers by the MR-PRESSO method (Supplementary Figures S1, S2). However, excluding those outliers did not substantially change the results (Table 2).

After excluding adiposity-related SNPs and adjusting for BMI in the MVMR analyses, the associations did not change substantially for HF and any stroke (Figure 2). There was suggestive evidence of an association between walking pace and AF after excluding adiposity-related SNPs but the association was weakened after adjusting for BMI. We also found that the estimates on IS and CES were fully attenuated after excluding adiposity-related SNPs or adjusting for BMI although the trend of inverse associations remained (Figure 2).

### Table 2: Sensitivity analyses of the associations of genetically predicted self-reported walking pace with cardiovascular diseases.

| Outcome (study) | MR method | SNP | OR (95% CI) | p-value |
|-----------------|-----------|-----|-------------|---------|
| AF (Nielsen et al.) | IVW | 72 | 0.577 (0.442, 0.755) | 5.87 × 10⁻⁶ |
|                  | Weighted median | 72 | 0.643 (0.476, 0.868) | 3.94 × 10⁻³ |
|                  | MR-RAPS | 72 | 0.564 (0.434, 0.733) | 1.81 × 10⁻⁵ |
|                  | MR-Egger | 72 | 1.041 (0.347, 3.117) | 0.944 |
|                  | MR-PRESSO | 70 | 0.569 (0.449, 0.720) | 1.34 × 10⁻⁵ |
| HF (HERMES) | IVW | 73 | 0.307 (0.229, 0.413) | 5.31 × 10⁻¹⁵ |
|                  | Weighted median | 73 | 0.299 (0.209, 0.427) | 3.38 × 10⁻¹¹ |
|                  | MR-RAPS | 73 | 0.308 (0.232, 0.409) | 4.59 × 10⁻¹⁶ |
|                  | MR-Egger | 73 | 0.479 (0.131, 1.748) | 0.269 |
|                  | MR-PRESSO | 71 | 0.311 (0.237, 0.408) | 2.97 × 10⁻¹² |
| AS (MEGASTROKE) | IVW | 72 | 0.540 (0.388, 0.752) | 2.63 × 10⁻⁴ |
|                  | Weighted median | 72 | 0.567 (0.370, 0.869) | 0.009 |
|                  | MR-RAPS | 72 | 0.548 (0.373, 0.805) | 0.002 |
|                  | MR-Egger | 72 | 0.216 (0.050, 0.939) | 0.045 |
|                  | MR-PRESSO | NA | NA | NA |
| IS (MEGASTROKE) | IVW | 72 | 0.604 (0.427, 0.853) | 0.004 |
|                  | Weighted median | 72 | 0.560 (0.355, 0.883) | 0.013 |
|                  | MR-RAPS | 72 | 0.610 (0.422, 0.891) | 0.009 |
|                  | MR-Egger | 72 | 0.324 (0.069, 1.516) | 0.157 |
|                  | MR-PRESSO | NA | NA | NA |
| LAS (MEGASTROKE) | IVW | 72 | 0.676 (0.319, 1.434) | 0.308 |
|                  | Weighted median | 72 | 0.496 (0.172, 1.434) | 0.196 |
|                  | MR-RAPS | 72 | 0.713 (0.315, 1.614) | 0.417 |
|                  | MR-Egger | 72 | 0.181 (0.006, 5.980) | 0.327 |
|                  | MR-PRESSO | NA | NA | NA |
| SVS (MEGASTROKE) | IVW | 72 | 0.603 (0.270, 1.349) | 0.218 |
|                  | Weighted median | 72 | 0.647 (0.221, 1.897) | 0.428 |
|                  | MR-RAPS | 72 | 0.690 (0.289, 1.645) | 0.402 |
|                  | MR-Egger | 72 | 0.165 (0.005, 5.891) | 0.327 |
|                  | MR-PRESSO | NA | NA | NA |
| CES (MEGASTROKE) | IVW | 72 | 0.492 (0.259, 0.934) | 0.030 |
|                  | Weighted median | 72 | 0.430 (0.189, 0.979) | 0.044 |
|                  | MR-RAPS | 72 | 0.490 (0.247, 0.973) | 0.042 |
|                  | MR-Egger | 72 | 0.074 (0.004, 1.341) | 0.082 |
|                  | MR-PRESSO | NA | NA | NA |
| RA (Negative control) | IVW | 71 | 0.771 (0.42, 1.417) | 0.402 |
|                  | Weighted median | 71 | 1.000 (0.494, 2.023) | 1.000 |
|                  | MR-RAPS | 71 | 0.771 (0.401, 1.481) | 0.434 |
|                  | MR-Egger | 71 | 0.747 (0.038, 14.611) | 0.848 |
|                  | MR-PRESSO | NA | NA | NA |

Abbreviations: MR, Mendelian randomization; SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; AF, atrial fibrillation; IVW, inverse variance weighted; MR-RAPS, MR-robust-adjusted profile score; MR-PRESSO, MR-pleiotropy residual sum and outlayer; HF, heart failure; AS, any stroke; IS, ischemic stroke; LAS, large artery stroke; SVS, small vessel stroke; CES, cardioembolic stroke; RA, rheumatoid arthritis; NA, not available.
DISCUSSION

We conducted a two-sample MR study to investigate whether genetically determined walking pace was causally associated with the CVD risks. Our findings indicated that genetically predicted increasing walking pace was related to lower risks of AF, HF, any stroke, IS, and CES.

A previous study showed that walking pace was significantly associated with the risk of AF, with individuals with the pace of 2–3 miles per hour (mph) and >3 mph associated with 32% (multivariable relative risk, 0.68; 95% CI, 0.59, 0.77; \( p < 0.001 \)) and 41% (multivariable relative risk, 0.59; 95% CI, 0.48, 0.74; \( p < 0.001 \)) lower risk of AF, respectively, compared to pace <2 mph (Mozaffarian et al., 2008). However, using the Multi-Ethnic Study of Atherosclerosis Typical Week Physical Activity Survey, Mokhayeri et al. (2017) concluded that walking pace was not associated with AF incidence. These inconsistent results from observational studies might be biased by insufficient follow-up duration and small sample size as well as unmeasured confounding factors, such as age, gender, and study populations. In this study, we performed MR analyses with summary-level data derived from large-scale GWAS meta-analysis conducted by Nielsen et al. and found that brisk walking pace was associated with a reduced risk of AF (OR, 0.577; 95% CI, 0.442, 0.755; \( p = 5.87 \times 10^{-6} \)), which was absent of confounding bias. Additionally, the significant association was replicated both in the FinnGen consortium and the meta-analysis combining these two datasets, indicating the reliability of our results and suggesting that walking faster could be a protective factor for AF.

Studies have demonstrated that physical activity was related to a reduced risk of developing HF (Djoussé et al., 2009). However, little is known about the effect of walking pace on the risk of HF. Pulignano et al. (2016) showed that walking pace was independently associated with hospitalization for HF [hazard ratio (HR), 0.697; 95% CI, 0.547, 0.899; \( p = 0.004 \)], and walking pace could improve risk stratification in older HF patients evaluated using the Cardiac and Comorbid Conditions Heart Failure score. Another prospective study suggested an inverse dose-response relationship between walking pace and the risk of HF, with moderate and high walking pace correlated with adjusted HRs of 0.53 (95% CI, 0.43, 0.66) and 0.30 (95% CI, 0.21, 0.44), respectively (Saevereid et al., 2014). Consistent with these two studies, we found that brisk walking pace was inversely associated with HF risk both in the primary analysis (OR, 0.307; 95% CI, 0.229, 0.413; \( p = 5.31 \times 10^{-15} \)) and the replication analysis (OR, 0.307; 95% CI, 0.209, 0.451; \( p = 1.92 \times 10^{-9} \)).

Regarding the relationship between walking pace and stroke, the findings of epidemiologic studies were inconclusive, and the data specific to stroke subtypes were limited. Several prospective studies suggested that a slow walking pace was associated with a higher risk of stroke (McGinn et al., 2008; Hayes et al., 2020), with HRs ranging from 1.45 to 1.69. A recent meta-analysis reported that individuals in the fastest walking pace category had a 44% lower risk of stroke than those in the slowest walking pace category [risk ratio (RR), 0.56; 95% CI, 0.48, 0.65] (Quan et al., 2020). They also observed a linear dose-response relationship, with the risk of stroke decreased by 13% for every 1 km/h increment in walking pace. The present MR study confirmed and extended the results of those studies, suggesting an inverse causal association between self-reported walking pace and the risk of any stroke, IS, and CES, with ORs being 0.540 for any stroke, 0.604 for IS, and 0.492 for CES. By contrast, such correlation was not observed in two other observational studies conducted by Jefferis et al. (2014) and Camargo et al. (2016). It is noteworthy that Jefferis et al. only examined the effect of walking pace on the risk of stroke in men, which limited the generalizability of the results. In
addition, confounders might occur, which could influence the outcome variables. Thus, more studies are warranted to confirm our results, especially those specific to stroke subtypes.

The causal estimates of walking pace on AF, IS, and CES were attenuated after excluding adiposity-related SNPs or adjusting for BMI, which suggested that the observed associations might be partially mediated through adiposity, a well-known risk factor for CVD (Khan et al., 2018). As adiposity management is an effective way to reduce CVD risk, increasing walking pace thus may be a potential way to reduce CVD risk. Whether walking pace could affect adiposity is uncertain, only a weak correlation of walking pace with BMI was observed by Halliday et al. (2020). Further studies are warranted to elucidate the association between walking pace and adiposity. In addition, it is notable that the causal associations for HF and any stroke remained after excluding adiposity-related SNPs and adjusting for BMI, indicating that increasing walking pace has a direct protective effect on HF and stroke.

This study has important implications for physical activity recommendations, as CVD remains the leading cause of mortality worldwide (Townsend et al., 2016). Our results showed that brisk walking pace was causally correlated with the reduced risk of several outcomes of CVD, including AF, HF, any stroke, IS, and CES, suggesting that guidelines should encourage people to increase their walking pace and maximize its health benefits in preventing CVD. In addition, walking is a safe, cost-effective, and accessible physical activity. A pace change may be more feasible than increasing the walking duration for those with adequate physical capacity (Stamatakis et al., 2019).

The present study had several strengths. We used the MR method to elucidate the causal associations between self-reported walking pace and several CVD outcomes, which avoided residual confounding bias and reverse causation. We also applied comprehensive sensitivity analyses and MVMR to assess the robustness of our study and minimize the potential pleiotropic effect. Moreover, we implemented summary-level statistics for outcomes from two different data sources. The results of the replication analyses were mainly consistent with our main results, supporting that our findings were reliable.

Nonetheless, some limitations should be considered. We only used self-reported data on walking pace using the ACE touchscreen questionnaire due to a lack of objectively measured summary-level data, which might lead to misclassification bias. However, it was reported that self-reported walking pace was highly correlated with actual and measured walking pace (Zeki Al Hazzouri et al., 2017). In addition, self-reported walking pace is considered a general indicator of an individual’s perceived health and physical frailty in the elderly (Binotto et al., 2018; Timmins et al., 2020). However, we did not perform additional analyses to check whether other conditions exerted an effect on CVD through walking pace. Further studies can take self-reported walking pace into account when they infer causal associations between potential risk factors and CVD. In addition, most of the individuals involved in our study were of European ancestry, limiting our generalizability to other ancestries. Pleiotropy is a potential limitation in any MR analyses. However, we detected no evidence of pleiotropy using the MR-Egger regression method. To minimize potential pleiotropy bias, we further re-conducted MR analyses by excluding adiposity-associated SNPs and adjusting for BMI. Last, selection bias has been increasingly recognized as a limitation of MR, mainly due to limited representativeness of the selected sample, attrition from an initially representative sample, and selecting sample strongly surviving the exposure (Schooling et al., 2020; Mendelian randomization, 2022). Since previous studies have reported that walking pace strongly affects survival (Celis-Morales et al., 2019; Timmins et al., 2020) and GWAS participants are typically recruited in middle age or older, selection bias can be present in our study.

CONCLUSION

In conclusion, this two-sample MR study showed that genetically predicted increasing walking pace was related to lower risks of AF, HF, any stroke, IS, and CES, suggesting that physical activity recommendations should encourage people to increase their walking pace in preventing CVD.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

LC and LZ: conceptualization; LC and XS: methodology and writing—original draft preparation; LC and YH: formal analysis; LC, XS, and YH: writing—review and editing; LZ: supervision and funding acquisition. All authors have read and agreed to the published version of the manuscript.

FUNDING

This work was supported by the National Natural Science Foundation of China (Grant Number 81873484) and the National Natural Science Foundation of China Youth Project (Grant Number 82000316).

ACKNOWLEDGMENTS

We thank all investigators and consortia for conducting GWAS involved in the present study and generously sharing the summary-level data.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2022.871302/full#supplementary-material
REFERENCES

Binotto, M. A., Lenardt, M. H., and Rodríguez-Martínez, M. D. C. (2018). Physical Frailty and Gait Speed in Community Elderly: a Systematic Review. Rev. Esc. Enferm. Usp. 52, e03392. doi:10.1590/S1980-220X2017028703392

Bowden, J., Davey Smith, G., and Burgess, S. (2015). Mendelian Randomization with Invalid Instruments: Effect Estimation and Bias Detection through Egger Regression. Int. J. Epidemiol. 44 (2), 512–525. doi:10.1093/ije/dyv080

Bowden, J., Davey Smith, G., Haycock, P. C., and Burgess, S. (2016). Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet. Epidemiol. 40 (4), 304–314. doi:10.1002/gepi.21965

Burgess, S., and Thompson, S. G. (2011). Avoiding Bias from Weak Instruments in Mendelian Randomization Studies. Int. J. Epidemiol. 40 (3), 755–764. doi:10.1093/ije/dyv036

Camargo, E. C., Weinstein, G., Beiser, A. S., Tan, Z. S., DeCarli, C., Kelly-Hayes, M., et al. (2016). Association of Physical Function with Clinical and Subclinical Brain Disease: The Framingham Offspring Study. J. Am. Med. Assoc. 315 (4), 1597–1608. doi:10.1001/jama.2016.3233

Celi-Morales, C. A., Gray, S., Petermann, F., Ilisromiitii, S., Welsh, P., Lyall, D. M., et al. (2019). Walking Pace Is Associated with Lower Risk of All-Cause and Cause-Specific Mortality. Med. Sci. Sports Exerc 51 (3), 472–480. doi:10.1249/ms.0000000000001795

Djoussé, L., Driver, J. A., and Gaziano, J. M. (2009). Relation between Modifiable Lifestyle Factors and Lifetime Risk of Heart Failure. JAMA 302 (4), 394–400. doi:10.1001/jama.2009.1062

Dumurgier, J., Elbaz, A., Ducimetière, P., Tavernier, B., Alpérovitch, A., and Halliday, S. J., Wang, L., Yu, C., Vickers, B. P., Newman, J. H., Fremont, R. D., et al. (2014). Association of Physical Function with Clinical and Subclinical Brain Disease and Compression of Morbidity. Int. J. Epidemiol. 43 (6), 1734–1739. doi:10.1093/ije/dyu304

McGinn, A. P., Kaplan, R. C., Verghese, J., Rosenbaum, D. M., Psaty, B. M., Baird, A. E., et al. (2008). Walking Speed and Risk of Incident Ischemic Stroke Among Postmenopausal Women. Stroke 39 (4), 1233–1239. doi:10.1161/strokeaha.107.500850

Mendelian randomization (2022). One Year of Methods Primers. Nat. Rev. Methods Prim. 2 (1), 7. doi:10.1038/s43586-021-00091-6

Molhayeri, Y., Hashemi-Nazari, S. S., Mansournia, M. A., Soori, H., and Khodakarim, S. (2017). The Association between Physical Activity and Atrial Fibrillation Applying the Heaviside Function in Survival Analysis: the Multi-Ethnic Study of Atherosclerosis. Epidemiol. Health 39, e2017024. doi:10.4178/eh.2017024

Mozaffarian, D., Furberg, C. D., Psaty, B. M., and Siscovick, D. (2008). Physical Activity and Incidence of Atrial Fibrillation in Older Adults. Circulation 118 (8), 800–807. doi:10.1161/circulationaha.108.785626

Murtagh, E. M., Nichols, L., Mohammed, M. A., Holder, R.,Neill, A. M., and Murphy, M. H. (2015). The Effect of Walking on Risk Factors for Cardiovascular Disease: an Updated Systematic Review and Meta-Analysis of Randomised Control Trials. Prev. Med. 72, 34–43. doi:10.1016/j.ypmed.2014.12.041

Nielsen, J. B., Thorølfdottir, R. B., Fritsche, L. G., Zhou, W., Skov, M. W., Graham, S. E., et al. (2018). Biobank-driven Genomic Discovery Yields New Insight into Atrial Fibrillation Biology. Nat. Genet. 50 (9), 1234–1239. doi:10.1038/s41588-018-0171-3

Okada, Y., Wu, D., Trynka, G., Raj, T., Teroa, C., Ikari, K., et al. (2014). Genetics of Rheumatoid Arthritis Contributes to Biology and Drug Discovery. Nature 506 (7488), 376–381. doi:10.1038/nature12873

Puligarno, G., Del Sindaco, D., Di Lenarda, A., Alunni, G., Senni, M., Tarantini, L., et al. (2016). Incremental Value of Gait Speed in Predicting Prognosis of Older Adults with Heart Failure. JACC Heart Fail. 4 (4), 289–298. doi:10.1016/j.jchf.2015.12.017

Quan, M., Xun, P., Wang, R., He, K., and Chen, P. (2020). Walking Pace and the Risk of Stroke: A Meta-Analysis of Prospective Cohort Studies. J. Sport Health Sci. 9 (6), 521–529. doi:10.1016/j.jshs.2019.09.005

Sæverud, H. A., Schohr, P., and Prescott, E. (2014). Speed and Duration of Walking and Other Leisure Time Physical Activity and the Risk of Heart Failure: a Prospective Cohort Study from the Copenhagen City Heart Study. PLoS One 9 (3), e89990. doi:10.1371/journal.pone.0089990

Schooling, C. M., Lopez, P. M., Yang, Z., Zhao, J. V., Au Yeung, S. L., and Huang, J. V. (2020). Use of Multivariable Mendelian Randomization to Address Biases Due to Competing Risk before Recruitment. Front. Genet. 11, 610852. doi:10.3389/fgene.2020.610852

Sekula, P., Del Greco M., Fattorino, C., and Köttgen, A. (2016). Mendelian Randomization as an Approach to Assess Causality Using Observational Data. J. Am. Soc. Nephrol. 27 (11), 3253–3265. doi:10.1681/asn.2016010098

Shah, S., Henry, A., Roselli, C., Lin, H., Sveinbjörnsson, G., Fatemifar, G., et al. (2020). Genome-wide Association and Mendelian Randomisation Analysis Provide Insights into the Pathogenesis of Heart Failure. Nat. Commun. 11 (1), 163. doi:10.1038/s41467-019-13690-5

Stamatakis, E., Williamson, C., Kelly, P., Sain, T., Murtagh, E. D., Ding, D., et al. (2019). Infographic. Self-Rated Walking Pace and All-Cause, Cardiovascular Mortality: Individual Participant Pooled Analysis of 50 225 Walkers from 11 Population British Cohorts. J. Sport Health Sci. 1381. doi:10.1016/j.jshs.2019.09.005

Timmins, I. R., Zaccardi, F., Nelson, C. P., Franks, P. W., Yates, T., and Dudbridge, F. (2020). Genome-wide Association Study of Self-Reported Walking Pace Suggests Beneficial Effects of Brisk Walking on Health and Survival. Commun. Biol. 3 (1), 634. doi:10.1038/s42003-020-01357-7

Townsend, N., Wilson, L., Bhatnagar, P., Wickramasinghe, K., Rayner, M., and Nichols, M. (2016). Cardiovascular Disease in Europe: Epidemiological Update 2016. Eur. Heart J. 37 (42), 3232–3245. doi:10.1093/eurheartj/ehw334

Verbanck, M., Chen, C.-Y., Neale, B., and Do, R. (2018). Detection of Widespread Horizontal Pleiotropy in Causal Relationships Inferred from Mendelian Randomization between Complex Traits and Diseases. Nat. Genet. 50 (5), 693–698. doi:10.1038/s41588-018-0099-7

Yavorska, O. O., and Burgess, S. (2017). MendelianRandomization: an R Package for Performing Mendelian Randomization Analyses Using Summarized Data. Int. J. Epidemiol. 46 (6), 1734–1739. doi:10.1093/ije/dyx034
Zeki Al Hazzouri, A., Mayeda, E. R., Elfassy, T., Lee, A., Odden, M. C., Thekkethala, D., et al. (2017). Perceived Walking Speed, Measured Tandem Walk, Incident Stroke, and Mortality in Older Latino Adults: A Prospective Cohort Study. *J. Gerontol. A Biol. Sci. Med. Sci.* 72 (5), 676–682. doi:10.1093/gerona/glw169

Zhao, Q., Wang, J., Hemani, G., Bowden, J., and Small, D. S. (2018). Statistical Inference in Two-Sample Summary-Data Mendelian Randomization Using Robust Adjusted Profile Score. *Ann. Statistics* 48 (3). doi:10.1214/19-aos1866

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Chen, Sun, He and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.